Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success

Key Takeaways LYRA shares jumped 355.5% this week after LYR-210 met the goal in the phase III ENLIGHTEN 2 CRS study. LYR-210 showed strong symptom relief and improved SNOT-22 scores at 24 weeks, starting as early as week 4. Lyra plans to discuss ENLIGHTEN 2 data with the FDA and may seek approval for LYR-210 in CRS without polyps.Shares of Lyra Therapeutics (LYRA) have skyrocketed 355.5% in a week after the company announced encouraging results from the late-stage study on its lead candidate, LYR-210, whi ...